金吾财讯 | 再鼎医药(ZLAB)盘前涨超9%，截至发稿，报31.1美元。消息面上，广发证券指出，对外授权短期看可以改善企业现金流支持企业继续投入研发，中长期看国内企业还能从合作中学习研发经验，提升自身的临床运营能力，因此对外授权仍将为创新药企出海的首选方案。BD只是本轮创新药价值重估的起点，展望下半年，持续跟踪医保商保谈判工作进展，关注WCLC、ESMO等国际学术会议重磅数据催化。
金吾财讯 | 再鼎医药(ZLAB)盘前涨超9%，截至发稿，报31.1美元。消息面上，广发证券指出，对外授权短期看可以改善企业现金流支持企业继续投入研发，中长期看国内企业还能从合作中学习研发经验，提升自身的临床运营能力，因此对外授权仍将为创新药企出海的首选方案。BD只是本轮创新药价值重估的起点，展望下半年，持续跟踪医保商保谈判工作进展，关注WCLC、ESMO等国际学术会议重磅数据催化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.